Department of Pediatrics

Model helps predict which infants may go on to develop NAS

A new Vanderbilt-designed prediction model may make it easier to determine which infants will go on to develop neonatal abstinence syndrome (NAS), a drug withdrawal syndrome in newborns that occurs after exposure to opioids during pregnancy.

New treatment for a rare obesity

Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity.

VUMC begins study of second COVID-19 vaccine

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

COVID treatment studied by VUMC gains FDA approval

Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Cancer centers nationwide join to address the impact of COVID-19 pandemic on cancer prevention and treatment

A consortium of 17 cancer centers in the United States, including Vanderbilt-Ingram Cancer Center, have come together to better understand the consequences of the COVID-19 pandemic in delaying cancer detection, care and prevention.

State of Pediatrics address reviews challenges, resiliency

Steven Webber, MBChP, MRCP, chair of the Department of Pediatrics, recently delivered his annual state of the department address to an ever-growing number of faculty, staff and trainees.

1 20 21 22 23 24 52